

Lobular Breast Cancer Alliance Inc.

Financial Statements

June 30, 2025 and 2024

Lobular Breast Cancer Alliance Inc.

June 30, 2025 and 2024

Table of Contents

Independent Auditor's Report	1
Statements of Financial Position	4
Statements of Activities and Changes in Net Assets	5
Statements of Functional Expenses	6
Statements of Cash Flows	7
Notes to the Financial Statements	8



Citrin Cooperman & Company, LLP
Certified Public Accountants

30 Braintree Hill Office Park, Suite 300
Braintree, MA 02184
T 781.356.2000 F 781.356.5450
citrincooperman.com

Independent Auditor's Report

To the Board of Directors and Management
Lobular Breast Cancer Alliance Inc.
White Horse Beach, Massachusetts

Opinion

We have audited the accompanying financial statements of Lobular Breast Cancer Alliance Inc. (a nonprofit organization), which comprise the statements of financial position as of June 30, 2025 and 2024, and the related statements of activities and changes in net assets, functional expenses, and cash flows for the years then ended, and the related notes to the financial statements.

In our opinion, the financial statements referred to above present fairly, in all material respects, the financial position of Lobular Breast Cancer Alliance Inc. as of June 30, 2025 and 2024, and the changes in its net assets and its cash flows for the years then ended in accordance with accounting principles generally accepted in the United States of America.

Basis for Opinion

We conducted our audits in accordance with auditing standards generally accepted in the United States of America. Our responsibilities under those standards are further described in the Auditor's Responsibilities for the Audit of the Financial Statements section of our report. We are required to be independent of Lobular Breast Cancer Alliance Inc. and to meet our other ethical responsibilities in accordance with the relevant ethical requirements relating to our audits. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

Responsibilities of Management for the Financial Statements

Management is responsible for the preparation and fair presentation of the financial statements in accordance with accounting principles generally accepted in the United States of America, and for the design, implementation, and maintenance of internal control relevant to the preparation and fair presentation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, management is required to evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about Lobular Breast Cancer Alliance Inc.'s ability to continue as a going concern within one year after the date that the financial statements are available to be issued.

Auditor's Responsibilities for the Audit of the Financial Statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not absolute assurance and therefore is not a guarantee that an audit conducted in accordance with generally accepted auditing standards will always detect a material misstatement when it exists. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control. Misstatements are considered material if there is a substantial likelihood that, individually or in the aggregate, they would influence the judgment made by a reasonable user based on the financial statements.

In performing an audit in accordance with generally accepted auditing standards, we:

- Exercise professional judgment and maintain professional skepticism throughout the audit.
- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, and design and perform audit procedures responsive to those risks. Such procedures include examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of Lobular Breast Cancer Alliance Inc.'s internal control. Accordingly, no such opinion is expressed.
- Evaluate the appropriateness of accounting policies used and the reasonableness of significant accounting estimates made by management, as well as evaluate the overall presentation of the financial statements.
- Conclude whether, in our judgment, there are conditions or events, considered in the aggregate, that raise substantial doubt about Lobular Breast Cancer Alliance Inc.'s ability to continue as a going concern for a reasonable period of time.

We are required to communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit, significant audit findings, and certain internal control related matters that we identified during the audit.

Citrin Cooperman & Company, LLP

Braintree, Massachusetts
September 16, 2025

Lobular Breast Cancer Alliance Inc.

Statements of Financial Position

June 30, 2025 and 2024

	<u>2025</u>	<u>2024</u>
Assets		
Cash and cash equivalents	\$ 1,098,526	\$ 633,011
Prepaid expenses and other assets	7,969	7,453
Total assets	<u>\$ 1,106,495</u>	<u>\$ 640,464</u>
Liabilities and net assets		
Liabilities		
Accrued expenses	\$ 23,360	\$ 13,943
Accounts payable	-	28,260
Total liabilities	<u>23,360</u>	<u>42,203</u>
Net assets		
Net assets without donor restrictions	1,054,361	497,677
Net assets with donor restrictions	28,774	100,584
Total net assets	<u>1,083,135</u>	<u>598,261</u>
Total liabilities and net assets	<u>\$ 1,106,495</u>	<u>\$ 640,464</u>

See accompanying notes to the financial statements.

Lobular Breast Cancer Alliance Inc.

Statements of Activities and Changes in Net Assets

For the years ended June 30, 2025 and 2024

	Without Donor Restriction 2025	With Donor Restriction 2025	Total 2025	Without Donor Restriction 2024	With Donor Restriction 2024	Total 2024
Support and revenues						
Contributions	\$ 1,321,670	\$ 30,000	\$ 1,351,670	\$ 927,173	\$ 100,584	\$ 1,027,757
In-kind contributions	25,675	-	25,675	28,420	-	28,420
Interest income	29,054	-	29,054	14,877	-	14,877
Other income	23	-	23	459	-	459
Gain (loss) on investments	(1,280)	-	(1,280)	448	-	448
Net assets released from donor restrictions	101,810	(101,810)	-	-	-	-
Total support and revenues	<u>1,476,952</u>	<u>(71,810)</u>	<u>1,405,142</u>	<u>971,377</u>	<u>100,584</u>	<u>1,071,961</u>
Expenses						
Program	677,032	-	677,032	581,659	-	581,659
Management and general	113,592	-	113,592	90,878	-	90,878
Fundraising	129,644	-	129,644	99,440	-	99,440
Total expenses	<u>920,268</u>	<u>-</u>	<u>920,268</u>	<u>771,977</u>	<u>-</u>	<u>771,977</u>
Changes in net assets	556,684	(71,810)	484,874	199,400	100,584	299,984
Net assets at beginning of year	497,677	100,584	598,261	298,277	-	298,277
Net assets at end of year	<u>\$ 1,054,361</u>	<u>\$ 28,774</u>	<u>\$ 1,083,135</u>	<u>\$ 497,677</u>	<u>\$ 100,584</u>	<u>\$ 598,261</u>

See accompanying notes to the financial statements.

Lobular Breast Cancer Alliance Inc.

Statements of Functional Expenses

For the years ended June 30, 2025 and 2024

	Program 2025	Management and general 2025	Fundraising 2025	Total 2025
Payroll and related expenses	\$ 217,099	\$ 38,398	\$ 93,568	\$ 349,065
Research	326,500	-	-	326,500
Professional fees	68,346	66,761	11,502	146,609
Office and other	8,532	4,446	24,574	37,552
Scholarships and sponsorships	37,028	-	-	37,028
Travel	11,265	-	-	11,265
Advertising	8,262	1,185	-	9,447
Insurance	-	2,802	-	2,802
Total expenses	\$ 677,032	\$ 113,592	\$ 129,644	\$ 920,268

	Program 2024	Management and general 2024	Fundraising 2024	Total 2024
Payroll and related expenses	\$ 171,943	\$ 28,124	\$ 84,285	\$ 284,352
Research	262,500	-	-	262,500
Professional fees	70,950	51,183	7,770	129,903
Office and other	9,014	7,209	5,218	21,441
Scholarships and sponsorships	54,702	1,229	-	55,931
Travel	11,877	-	-	11,877
Advertising	673	125	2,167	2,965
Insurance	-	3,008	-	3,008
Total expenses	\$ 581,659	\$ 90,878	\$ 99,440	\$ 771,977

See accompanying notes to the financial statements.

Lobular Breast Cancer Alliance Inc.

Statements of Cash Flows

For the years ended June 30, 2025 and 2024

	<u>2025</u>	<u>2024</u>
Cash flows from operating activities		
Changes in net assets	\$ 484,874	\$ 299,984
Adjustments to reconcile changes in net assets to net cash provided by operating activities		
Net realized and unrealized loss (gain) on donated investments	1,280	(448)
Non-cash contributions of donated investments	(72,488)	(83,160)
Changes in operating assets and liabilities		
Contributions receivable	-	49,139
Prepaid expenses and other assets	(516)	(5,822)
Accounts payable	(28,260)	(45,046)
Accrued expenses	9,417	5,138
Net cash provided by operating activities	<u>394,307</u>	<u>219,785</u>
Cash provided by investing activities		
Proceeds from sale of donated investments	71,208	83,608
Net increase in cash and cash equivalents	<u>465,515</u>	<u>303,393</u>
Cash and cash equivalents at beginning of year	633,011	329,618
Cash and cash equivalents at end of year	<u><u>\$ 1,098,526</u></u>	<u><u>\$ 633,011</u></u>

See accompanying notes to the financial statements.

Lobular Breast Cancer Alliance Inc.

Notes to the Financial Statements

June 30, 2025 and 2024

1. ORGANIZATION

Lobular Breast Cancer Alliance Inc. (the Organization) is a nonprofit organization established in 2021. The Organization is dedicated to making all who are touched by Invasive Lobular Breast Cancer (ILC) aware of its unique characteristics and critical need for more research. The Organization's goals are to be the primary source for information on ILC studies, clinical trials and educational tools; to foster partnerships among patients, scientists, clinicians and breast cancer organizations to increase dialogue about ILC and research advocacy; and to fund vital ILC research. Support is provided by contributions from foundations, individuals and corporations.

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Basis of accounting - The financial statements of the Organization have been prepared on the accrual basis. The significant accounting policies followed are described below to enhance the usefulness of the financial statements to the reader.

Financial statement presentation - The Organization follows the Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) Subtopic *Presentation of Financial Statements of Not-for-Profit Entities*. Net assets, revenues, expenses, gains and losses are classified based on the existence or absence of donor-imposed restrictions. Accordingly, net assets and changes therein are classified as follows:

Net assets without donor restrictions - Net assets that are not subject to donor-imposed restrictions and may be expended for any purpose in performing the primary objectives of the Organization. These net assets may be used at the discretion of the Organization's management and the board of directors.

Net assets with donor restrictions - Net assets subject to stipulations imposed by donors and grantors. Some donor restrictions are temporary in nature; those restrictions will be met by actions of the Organization or by the passage of time. Other donor restrictions are perpetual in nature, where by the donor had stipulated the funds be maintained in perpetuity. At June 30, 2025 and 2024, the Organization did not have any net assets with donor restrictions that were perpetual in nature.

Use of estimates - The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America (U.S. GAAP) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.

Lobular Breast Cancer Alliance Inc.

Notes to the Financial Statements

June 30, 2025 and 2024

Cash and cash equivalents - Cash and cash equivalents consist of cash on hand, demand deposits, and a money market account. The Organization maintains its cash in bank deposits in accounts, which at times may exceed federally insured limits. At June 30, 2025, the Organization has a money market account which is not insured under the Federal Deposit Insurance Corporation (FDIC); however, funds are held with an institution who is a member of Securities Investor Protection Corporation. At June 30, 2025, balances in excess of federally insured limits totaled \$348,369. At June 30, 2024, balances in excess of federally insured limits totaled \$58,831. The Organization considers all short-term investment securities with a maturity of three months or less to be cash equivalents.

Revenue recognition - Revenue is reported as increases in net assets without donor restrictions unless use of the related assets is limited by donor-imposed restrictions. Expenses are reported as decreases in net assets without donor restrictions. Gains and losses on assets or liabilities are reported as increases or decreases in net assets without donor restrictions unless their use is restricted by explicit donor stipulations or by law. Expirations of net assets with donor restrictions (i.e., the donor-stipulated purpose has been fulfilled and/or the stipulated time period has elapsed) are reported as net assets released from donor restrictions.

Grants and contributions - Contributions of cash and other assets are presented as restricted support if they are received with donor stipulations that limit the use of the donated assets. When a donor restriction expires, that is, when a stipulated time restriction ends or purpose restriction is accomplished, net assets with donor restrictions are reclassified to net assets without donor restrictions and reported in the statements of activities and changes in net assets as net assets released from donor restrictions. Grants and contributions subject to donor-imposed stipulations that are met in the same reporting period are reported as revenues without donor restrictions.

Grants and contributions, including unconditional promises to give, are recognized as revenues in the period received. Conditional promises to give, that is, those with a measurable performance or other barrier, are not recognized until they become unconditional, that is, at the time when the conditions on which they depend are substantially met.

Grants and contributions of assets other than cash are reported at their estimated fair value. Grants and contributions to be received after one year are discounted at an appropriate discount rate commensurate with the risk involved. Amortization of the discount is recorded as additional grant and contribution revenue in accordance with donor-imposed or grantor-imposed restrictions, if any, on the grants and contributions.

In-Kind contributions - Contributions of services that create or enhance non-financial assets or that require specialized skills, which are provided by individuals possessing those skills and would typically need to be purchased if not provided by donation, are recorded at their fair values in the period received. The amounts reflected in the accompanying statements of activities and changes in net assets as "in-kind contributions" are offset by like amounts included in expenses.

Lobular Breast Cancer Alliance Inc.

Notes to the Financial Statements

June 30, 2025 and 2024

Advertising - Advertising costs are charged to expense as incurred. The Organization incurred advertising costs of \$9,447 and \$2,965 during the years ended June 30, 2025 and 2024, respectively, which is included in advertising expense in the accompanying statements of functional expenses.

Income taxes - The Organization is exempt from income tax pursuant to Section 501(c)(3) of the Internal Revenue Code (IRC) and, accordingly, no provision for income taxes has been recorded in the accompanying financial statements. The Organization is subject to federal and state income taxes on unrelated business income, if any. The Organization files informational tax returns as required by the IRC.

The Organization accounts for uncertain tax positions in accordance with FASB ASC Topic 740, *Income Taxes*. This topic prescribes a recognition threshold measurement process for financial statement recognition of uncertain tax positions taken or expected to be taken in a tax return. The Topic also provides guidance on recognition, derecognition, classification, interest and penalties, accounting in interim periods, disclosure and transition. At June 30, 2025 and 2024, management believes that the Organization has no material uncertain tax positions.

Functional allocation of expenses - Expenses have been summarized on a functional basis in the accompanying financial statements. Certain costs have been allocated among the program and supporting services benefited on a reasonable basis that is consistently applied. The expenses that are allocated include payroll and related expenses, professional fees, scholarships and sponsorships, office and other, and advertising, which are allocated on the basis of estimates of time and effort.

Subsequent events - The Organization has evaluated all events subsequent to the statement of financial position date of June 30, 2025, through the date which the financial statements were available to be issued, September 16, 2025, and has determined that there are no subsequent events that require disclosure under FASB ASC Topic 855, *Subsequent Events*.

3. AVAILABILITY AND LIQUIDITY

The following represents the Organization's financial assets as of June 30, 2025 and 2024:

	<u>2025</u>	<u>2024</u>
Cash and cash equivalents	\$ 1,098,526	\$ 633,011
Less: net assets with donor restrictions	28,774	100,584
Financial assets available to meet cash needs for general expenditures within one year	<u>\$ 1,069,752</u>	<u>\$ 532,427</u>

The Organization's goal is to maintain readily available financial assets to meet three months of operating expenses. As part of management's liquidity plan, all cash is maintained in checking, money market and savings accounts and is readily available for use.

Lobular Breast Cancer Alliance Inc.

Notes to the Financial Statements

June 30, 2025 and 2024

4. IN-KIND CONTRIBUTIONS

For the years ended June 30, 2025 and 2024, in-kind contributions in the form of donated services recognized in the statements of activities and changes in net assets included \$25,675 and \$28,420, respectively. The total amount of these donated services was comprised of donated legal services. The related expense is recorded in the statements of functional expenses as professional fees. Donations of legal services are valued based on the number of hours worked and billing rates for similar services that the Organization would otherwise have to purchase.

5. NET ASSETS WITH DONOR RESTRICTIONS

At June 30, 2025 and 2024, the Organization had \$28,774 and \$100,584, respectively, of net assets with donor restrictions for the specific purpose of education and research funding. Net assets are released from donor restrictions by incurring expenses or costs satisfying the restricted purpose or by occurrence of events specified by the donor. There were \$101,810 of net assets released from restrictions during the year ended June 30, 2025, related to research funding. There were no net assets released from restrictions during the year ended June 30, 2024.

6. RETIREMENT PLAN

Effective January 1, 2024, the Organization adopted a 403(b) defined contribution plan (the Plan) for all eligible employees of the Organization. The Plan allows employees to contribute up to 90% of eligible compensation, not to exceed the limits set by the Internal Revenue Service. The Organization can make discretionary contributions. There were no such contributions made during the years ended June 30, 2025 and 2024.

7. CONCENTRATIONS

During the year ended June 30, 2025, one donor accounted for approximately 37% of total support and revenue. During the year ended June 30, 2024, one donor accounted for approximately 24% of total support and revenue.

Lobular Breast Cancer Alliance Inc.

Notes to the Financial Statements

June 30, 2025 and 2024

8. CONDITIONAL GRANT AGREEMENTS

During the year ended June 30, 2025, \$110,000 of prior year conditional grant agreements were disbursed. During the year ended June 30, 2025, new conditional grant agreements were entered into and resulted in disbursements of \$216,500, with a remaining payment of \$107,500 to be paid during the year ending June 30, 2027, when grant conditions have been met. Total grant amount funding disbursed during the year ended June 30, 2025 was \$326,500.

During the year ended June 30, 2024, \$57,500 of a prior year conditional grant agreement was disbursed. During the year ended June 30, 2024, new grant agreements were entered into and resulted in disbursements of an additional \$205,000 to fund research grants and to administer them, for a total grant funding amount for June 30, 2024 of \$262,500.